Plunkett Research Online: Autolus Therapeutics PLC

AUTOLUS THERAPEUTICS PLC (AUTL:NAS) Company Profile, Corporate Revenues, Growth, Market Size, Analysis, Business Forecasts, Market Share, Metrics, SWOT

Autolus Therapeutics PLC is a biopharmaceutical company. It is engaged in the development of next-generation programmed T cell therapies for the treatment of cancer. The company's pipeline includes AUTO1, AUTO2, AUTO3, AUTO4, and others......



Autolus Therapeutics PLC
Ticker: AUTL
Exchange: NAS
Parent Company:
Year Established:
Employees:
Fiscal Year Ends in

Phone: 44 2038296230
Fax:
Address: 58 Wood Lane
Forest House, White City
London, W12 7RZ United Kingdom

Types Of Business
Industry Ranks

Industry NAICS code:

Biotechnology

Ranks not available
ContactsDescription

Autolus Therapeutics PLC is a biopharmaceutical company. It is engaged in the development of next-generation programmed T cell therapies for the treatment of cancer. The company's pipeline includes AUTO1, AUTO2, AUTO3, AUTO4, and others......See More See More

Auditor: EY
Legal Advisor:
$USD, In whole numbers,
except marked * or %
20192018201820172016
Financials
    Revenue
    Cost of Revenue
    Gross Margin %
    R&D Expense
    Operating Income
    Operating Margin %
    SGA Expense
    Net Income
    Earnings Per Share
    Dividends
    Book Value Per Share
    Operating Cash Flow
    Capital Expenditure
    Free Cash Flow
Profitability
    EBITDA
    Return on Assets %
    Return on Equity %
    Net Margin %
    Assets Turnover
    Financial Leverage
Brands, Divisions and AffiliatesTop Salaries
NameTitleSalary (GBP)Bonus (GBP)
Other ThoughtsCorporate Culture

Apparent Female Officers or Directors: